Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | FES | P07332 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31635975 | 0.88 | CDK2 (0.46) | AURKAJAK2PRKD3MAP4K4FGFR1 | |
| SCHEMBL1516742 | 0.88 | CDK2 (0.46) | AURKAJAK2PRKD3MAP4K4FGFR1 | |
| SCHEMBL8478533 | 0.87 | PLK4 (0.44) | AURKAJAK2PRKD3MAP4K4FGFR1 | |
| SCHEMBL9888004 | 0.87 | CDK2 (0.44) | AURKAJAK2PRKD3MAP4K4FGFR1 | |
| SCHEMBL28512135 | 0.84 | DYRK1A (0.48) | AURKAJAK2PRKD3MAP4K4FGFR1 | |
| SCHEMBL4828101 | 0.84 | AURKA (0.54) | AURKAJAK2PRKD3MAP4K4FGFR1 | |
| SCHEMBL28046056 | 0.84 | BRAF (0.53) | AURKAJAK2PRKD3MAP4K4FGFR1 | |
| SCHEMBL31635978 | 0.83 | PKM (0.49) | AURKAJAK2MAP4K4FGFR1FLT1 | |
| SCHEMBL25294215 | 0.82 | LMNA (0.42) | AURKAMAP4K4FGFR1FLT1KDR | |
| SCHEMBL25251383 | 0.82 | LMNA (0.56) | BRAFLMNARAB9AMAP3K7TAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| EP-2925319-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | University Of Rochester (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014085795-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014085795-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2576549-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | University of Rochester (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | AURKA 385/4885JAK2 2895/4885PRKD3 279/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | AURKA 305/4885JAK2 623/4885PRKD3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.